

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): February 24, 2022

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact Name of Registrant as Specified in Its Charter)

**Delaware
(State or Other Jurisdiction
of Incorporation)**

**001-35547
(Commission
File Number)**

**36-4392754
(IRS Employer
Identification No.)**

**222 Merchandise Mart Plaza, Suite 2024, Chicago, Illinois 60654
(Address of Principal Executive Offices) (Zip Code)**

Registrant's Telephone Number, Including Area Code: (800) 334-8534

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<u>Title of Each Class</u>	<u>Trading Symbol</u>	<u>Name of Each Exchange on which Registered</u>
Common Stock, par value \$0.01 per share	MDRX	The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

Indicated by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On February 24, 2022, Allscripts Healthcare Solutions, Inc., a Delaware corporation (the “Company”) issued a press release regarding the Company’s financial results for the three and twelve months ended December 31, 2021. A copy of the press release is attached hereto as Exhibit 99.1.

The information furnished pursuant to this Item shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.**(d) Exhibits.**

Exhibit Number	Exhibit Description
99.1 104	Press release issued by Allscripts Healthcare Solutions, Inc. on February 24, 2022 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Date: February 24, 2022

By: /s/ Rick Poulton
Rick Poulton
President and Chief Financial Officer

Allscripts Announces Fourth Quarter and Fiscal Year 2021 Results

- *Fourth quarter GAAP diluted EPS of \$0.68; non-GAAP diluted EPS of \$0.79*
- *Fourth quarter bookings of \$219 million up 21% from the fourth quarter of 2020*
- *Generated \$66 million of cash flow from continuing operations in the quarter*

CHICAGO--(BUSINESS WIRE)--February 24, 2022--Allscripts Healthcare Solutions, Inc. (Nasdaq: MDRX) (Allscripts) announced its financial results for the three and twelve months ended December 31, 2021.

Bookings⁽¹⁾ were \$219 million in the fourth quarter of 2021. This result compares with \$181 million in the fourth quarter of 2020. Contract revenue backlog totaled \$3.8 billion as of December 31, 2021.

Fourth quarter 2021 revenue was \$392 million compared with \$386 million in the fourth quarter of 2020.

On a GAAP basis in the fourth quarter of 2021, income from operations was \$41 million compared with a loss from operations in the fourth quarter of 2020 of \$68 million. Non-GAAP income from operations in the fourth quarter of 2021 was \$65 million compared with \$47 million in the fourth quarter of 2020.

GAAP net income in the fourth quarter of 2021 totaled \$87 million compared with \$728 million in the fourth quarter of 2020. GAAP net income in the fourth quarter of 2020 included the gain on sale from the divestiture of two businesses, which contributed a combined \$793 million to net income. Non-GAAP net income in the fourth quarter of 2021 was \$99 million compared with \$31 million in the fourth quarter of 2020.

GAAP diluted earnings per share in the fourth quarter of 2021 were \$0.68 compared with \$4.82 in the fourth quarter of 2020. GAAP diluted earnings per share in the fourth quarter 2020 included the gain on sale from the divestiture of two businesses, which contributed a combined \$5.25 to earnings per share. Non-GAAP diluted earnings per share in the fourth quarter of 2021 was \$0.79 compared with \$0.20 in the fourth quarter of 2020.

Adjusted EBITDA totaled \$94 million in the fourth quarter of 2021, compared with \$77 million in the fourth quarter of 2020. For the full year ended December 31, 2021, GAAP income from operations was \$77 million compared to a loss of \$131 million for 2020 and Adjusted EBITDA was \$301 million compared to \$225 million in 2020.

For the full year ended December 31, 2021, cash flow from continuing operations was \$248 million compared with \$12 million in 2020, and free cash flow for the full year 2021 was \$170 million compared with (\$93 million) in 2020.

Stock repurchases totaled \$108 million in the fourth quarter. As previously announced, a new share repurchase program approved by the Board of Directors allows Allscripts to purchase up to \$250 million of its common stock and does not have a termination date.

“Allscripts delivered another strong quarter, reporting significant year-over-year growth in bookings, operating income, Adjusted EBITDA, and free cash flow. 2021 was a year of forward momentum for our company, as we made considerable, positive gains winning with our clients, shareholders, and talent,” said Paul M. Black, Allscripts Chief Executive Officer. “As we look ahead, we will continue to drive meaningful outcomes for our clients, improved margins, and free cash flow generation.”

2022 Financial Outlook⁽²⁾

For the full year 2022, Allscripts currently expects to achieve:

- Consolidated free cash flow from continuing operations between \$165 million and \$175 million
 - Consolidated revenue growth of 1% to 2%
-

Conference Call

Allscripts will conduct a conference call today, Thursday, February 24th, 2022, at 4:30 PM Eastern Time to discuss its earnings release and other information. Participants may access the conference call via webcast at <http://investor.allscripts.com>. Participants also may access the conference call by dialing +1 (877) 269-7756 or +1 (201) 689-7817 (international) and requesting Conference ID # 13726412.

A replay of the call will be available approximately two hours after the conclusion of the call, for a period of four weeks, on the Allscripts Investor Relations website or by calling +1 (877) 660-6853 or +1 (201) 612-7415 - Conference ID # 13726412.

Supplemental and non-GAAP financial information is also available at <http://investor.allscripts.com>.

Footnotes

- (1) Bookings reflect the value of executed contracts for software, hardware and other client services on a continuing operations basis.
- (2) In providing financial guidance, the company does not reconcile Adjusted EBITDA and free cash flow to the corresponding GAAP financial measures. Allscripts does not provide guidance for the various reconciling items since certain items that impact GAAP net operating income and operating cash flow such as acquisition-related amortization, asset impairment charges and restructuring and other costs, any of which may be significant, are outside of its control and/or cannot be reasonably predicted. Please see the "Explanation of Non-GAAP Financial Measures" at the end of this press release for detailed information on calculating non-GAAP measures. For a reconciliation of other non-GAAP financial measures, see the non-GAAP financial reconciliation tables in this release (Tables 4, 5 and 6).

NOTE: All percentage changes described within this press release are calculated from full dollar amounts as illustrated in the accompanying financial statements and Allscripts Supplemental Financial Data Workbook, posted on the Investor Relations website. Rounding differences may occur when individually calculating percentages or totals from rounded amounts included within the press release body compared to full dollar amounts in the tables.

About Allscripts

Allscripts (Nasdaq: MDRX) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. To learn more, visit www.allscripts.com, [Twitter](#), [YouTube](#) and [It Takes A Community: The Allscripts Blog](#).

© 2022 Allscripts Healthcare, LLC and/or its affiliates. All Rights Reserved.

Allscripts, the Allscripts logo, and other Allscripts marks are trademarks of Allscripts Healthcare, LLC and/or its affiliates. All other products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Allscripts Healthcare, LLC and/or its affiliates.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our 2022 outlook, profitability initiatives, strategic priorities and client outcomes. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “can,” “may,” “look forward,” “pipeline” and similar terms. Actual results could differ significantly from those set forth in the forward-looking statements, and reported results should not be considered an indication of future performance or events.

Certain factors that could cause our actual results to differ materially from those described in the forward-looking statements include, but are not limited to: our ability to achieve the margin targets associated with our margin improvement initiatives within the contemplated time periods, if at all; the magnitude, severity and duration of the COVID-19 pandemic, including the impacts of the pandemic, along with the impacts of our responses and the responses by governments and other businesses to the pandemic, on our business, our employees, our clients and our suppliers; security breaches resulting in unauthorized access to our or our clients’ computer systems or data, including denial-of-services, ransomware or other Internet-based attacks; the failure by Practice Fusion to comply with the terms of the settlement agreements with the U.S. Department of Justice (the “DOJ”); the costs and burdens of compliance by Practice Fusion with the terms of its settlement agreements with the DOJ; additional investigations and proceedings from governmental entities or third parties other than the DOJ related to the same or similar conduct underlying the DOJ’s investigations into Practice Fusion’s business practices; our ability to recover from third parties (including insurers) any amounts paid in connection with Practice Fusion’s settlement agreements with the DOJ and related inquiries; the expected financial results of businesses acquired by us; the successful integration of businesses acquired by us; the anticipated and unanticipated expenses and liabilities related to businesses acquired by us, including the civil investigation by the U.S. Attorney’s Office involving our Enterprise Information Solutions business; our failure to compete successfully; consolidation in our industry; current and future laws, regulations and industry initiatives; increased government involvement in our industry; the failure of markets in which we operate to develop as quickly as expected; our or our customers’ failure to see the benefits of government programs; changes in interoperability or other regulatory standards; our ability to maintain and expand our business with existing clients or effectively transition clients to newer products; the effects of the realignment of our sales, services and support organizations; market acceptance of our products and services; the unpredictability of the sales and implementation cycles for our products and services; our ability to manage future growth; our ability to introduce new products and services; our ability to establish and maintain strategic relationships; risks associated with investments and acquisitions; the performance of our products; our ability to protect our intellectual property rights; the outcome of legal proceedings involving us; our ability to hire, retain and motivate key personnel; performance by our content and service providers; liability for use of content; price reductions; our ability to license and integrate third-party technologies; risks related to global operations; variability of our quarterly operating results; risks related to our outstanding indebtedness; changes in tax rates or laws; business disruptions; our ability to maintain proper and effective internal controls; and asset and long-term investment impairment charges. Additional information about these and other risks, uncertainties, and factors affecting our business is contained in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Qs. We do not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in our business, financial condition or operating results over time.

Table 1
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Balance Sheets
(In millions)
(Unaudited)

	December 31, 2021	December 31, 2020
ASSETS		
Current assets:		
Cash and cash equivalents	\$188.3	\$531.1
Restricted cash	2.2	6.4
Accounts receivable, net	327.1	347.3
Contract assets	124.8	106.7
Income tax receivable	0.0	25.4
Prepaid expenses and other current assets	118.9	136.3
Total current assets	<u>\$761.3</u>	<u>\$1,153.2</u>
Fixed assets, net	47.9	72.2
Software development costs, net	172.1	193.2
Intangible assets, net	235.9	286.6
Goodwill	974.5	974.7
Deferred taxes, net	6.6	5.8
Contract assets - long-term	56.8	43.7
Right-of-use assets - operating leases	68.9	96.6
Other assets	101.2	91.6
Total assets	<u><u>\$2,425.2</u></u>	<u><u>\$2,917.6</u></u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$16.9	\$35.9
Accrued expenses	92.5	100.2
Accrued compensation and benefits	92.2	118.8
Deferred revenue	325.9	334.8
Current operating lease liabilities	19.6	22.3
Current liabilities attributable to discontinued operations	0.0	322.8
Total current liabilities	<u>547.1</u>	<u>934.8</u>
Long-term debt	350.1	167.6
Deferred revenue	4.4	3.4
Deferred taxes, net	16.6	18.2
Long-term operating lease liabilities	64.8	93.5
Other liabilities	34.1	33.9
Total liabilities	<u>\$1,017.1</u>	<u>\$1,251.4</u>
Total stockholders' equity	<u>\$1,408.1</u>	<u>\$1,666.2</u>
Total liabilities and stockholders' equity	<u><u>\$2,425.2</u></u>	<u><u>\$2,917.6</u></u>

Table 3
Allscripts Healthcare Solutions, Inc.
Condensed Consolidated Statements of Cash Flows
(In millions)
(Unaudited)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2021	2020	2021	2020
Cash flows from operating activities:				
Net income (loss)	\$87.3	\$727.8	\$134.4	\$700.4
Less: Income(loss) from discontinued operations	0.0	792.5	0.5	833.0
Income (loss) from continuing operations	\$87.3	(\$64.7)	\$133.9	(\$132.6)
Non-cash adjustments to net income (loss):				
Depreciation and amortization	43.1	46.4	176.1	192.3
Non-cash lease expense, net	(0.8)	0.9	(3.8)	1.4
Stock-based compensation expense	9.3	8.1	35.2	34.0
Deferred Taxes	(0.4)	(6.2)	(2.1)	(3.3)
Impairment of assets and long-term investments	0.0	74.7	11.8	76.6
Gain on sale of businesses, net	0.0	0.0	(8.4)	0.0
Other (income) loss, net	(61.4)	(4.9)	(70.9)	(23.1)
Total non-cash adjustments to net income (loss)	(10.2)	119.0	137.9	277.9
Cash impact of changes in operating assets and liabilities:				
Assets	(0.3)	(63.9)	12.8	0.7
Liabilities	(10.5)	65.2	(36.3)	13.5
Accrued DOJ settlement	0.0	(58.4)	0.0	(147.2)
Total cash impact of changes on operating assets and liabilities	(10.8)	(57.1)	(23.5)	(133.0)
Net cash provided by (used in) operating activities - Continuing operations	66.3	(2.8)	248.3	12.3
Net cash provided by (used in) operating activities - Discontinued operations	(1.2)	(175.8)	(323.7)	(119.0)
Net cash provided by (used in) operating activities	65.1	(178.6)	(75.4)	(106.7)
Cash flows from investing activities:				
Capital expenditures	(0.7)	(9.2)	(5.3)	(17.0)
Capitalized software	(17.8)	(16.3)	(73.3)	(88.0)
Sale of businesses and other investments, net of cash divested and distributions received	61.2	1,710.0	68.8	1,734.9
Purchases of equity securities, other investments and related intangible assets, net	0.0	(3.2)	(2.4)	(7.1)
Cash provided by (used in) investing activities - Continuing Operations	42.7	1,681.3	(12.2)	1,622.8
Cash provided by (used in) investing activities - Discontinued Operations	0.0	(1.2)	0.0	(7.6)
Net cash provided by (used in) investing activities	42.7	1,680.1	(12.2)	1,615.2
Cash flows from financing activities:				
Taxes paid related to net share settlement of equity awards	(0.1)	(0.4)	(14.0)	(5.9)
Payments for issuance costs on 0.875% Convertible Senior Notes	0.0	0.0	0.0	(0.8)
Repayment of Convertible Senior Notes	0.0	0.0	0.0	(352.3)
Credit facility payments	(25.0)	(1,140.0)	(75.0)	(1,315.0)
Credit facility borrowings, net of issuance costs	0.0	230.0	250.0	903.6
Repurchase of common stock	(108.5)	(279.6)	(417.5)	(334.9)
Payment of acquisition and other financing obligations	0.0	0.0	(2.4)	(4.4)
Net cash provided by (used in) financing activities	(133.6)	(1,190.0)	(258.9)	(1,109.7)
Effect of exchange rate changes on cash and cash equivalents	0.0	1.1	(0.5)	1.2
Net increase (decrease) in cash and cash equivalents	(25.8)	312.6	(347.0)	400.0
Cash, cash equivalents and restricted cash, beginning of period	216.3	224.9	537.5	137.5
Cash, cash equivalents and restricted cash, end of period	\$190.5	\$537.5	\$190.5	\$537.5

Table 4
Allscripts Healthcare Solutions, Inc.
Condensed Non-GAAP Financial Information
(In millions, except per share amounts and percentages)
(Unaudited)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2021	2020	2021	2020
Gross profit, as reported	\$169.0	\$161.0	\$619.6	\$565.7
Acquisition-related amortization	6.8	7.5	27.4	32.1
Stock-based compensation expense	1.4	1.5	5.6	6.0
Restructuring and other	0.0	(0.1)	0.0	2.8
Total non-GAAP gross profit	\$177.2	\$169.9	\$652.6	\$606.6
Income (loss) from operations, as reported	\$41.4	(\$68.1)	\$77.2	(\$130.9)
Acquisition-related amortization	12.5	13.8	50.6	57.8
Stock-based compensation expense	11.0	9.5	43.5	38.4
Restructuring and other	0.0	91.5	(0.0)	141.2
Total non-GAAP income from operations	\$64.9	\$46.7	\$171.3	\$106.5
Net income (loss) attributable to Allscripts Healthcare Solutions, Inc. stockholders, as reported	\$87.3	\$727.8	\$134.4	\$700.4
Loss (income) from discontinued operations	0.0	(16.8)	0.0	(71.4)
(Gain) on sale of business, net from discontinued operations	0.0	(1,156.5)	(0.6)	(1,156.5)
Income tax provision from discontinued operations	0.0	380.8	0.1	394.9
Income (loss) from continuing operations, net of tax	\$87.3	(\$64.7)	\$133.9	(\$132.6)
Acquisition-related amortization	12.5	13.8	50.6	57.7
Stock-based compensation expense	11.0	9.5	43.5	38.4
Restructuring and other	0.0	91.5	(0.0)	141.2
Non-cash charges to interest expense and other	1.4	1.2	0.2	16.1
Tax rate alignment	(13.3)	(19.9)	(33.6)	(41.7)
Non-GAAP net income attributable to Allscripts Healthcare Solutions, Inc.	\$98.9	\$31.4	\$194.6	\$79.1
Non-GAAP effective tax rate	24%	24%	24%	24%
Weighted shares outstanding - basic	120.1	150.9	130.1	159.3
Weighted shares outstanding - diluted	127.8	155.9	138.7	162.0
Less effect of convertible note hedges	(2.5)	0.0	(2.8)	0.0
Non-GAAP Weighted shares outstanding - diluted	125.3	155.9	135.9	162.0
GAAP Income (loss) from continuing operations per share - diluted	\$0.68	(\$0.43)	\$0.97	(\$0.83)
Non-GAAP Income (loss) per share - diluted	\$0.79	\$0.20	\$1.43	\$0.49

Table 5
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - Adjusted EBITDA
(In millions, except percentages)
(Unaudited)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2021	2020	2021	2020
Income (loss) from operations, as reported	\$41.4	(\$68.1)	\$77.2	(\$130.9)
Plus:				
Depreciation and amortization	41.3	43.9	168.6	176.0
Asset impairment charges	0.0	0.0	11.8	0.0
Stock-based compensation expense	11.0	9.5	43.5	38.4
Restructuring and other	0.0	91.5	0.0	141.2
Adjusted EBITDA	\$93.7	\$76.8	\$301.1	\$224.7
Adjusted EBITDA margin (a)	23.9%	19.9%	20.0%	15.0%

(a) Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by revenue.

Table 6
Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - Free Cash Flow
(In millions)
(Unaudited)

	Three Months Ended December 31,		Twelve Months Ended December 31,	
	2021	2020	2021	2020
Net cash provided by (used in) operating activities - continuing operations	\$66.3	(\$2.8)	\$248.3	\$12.3
Cash flows from investing activities:				
Capital expenditures	(0.7)	(9.2)	(5.3)	(17.0)
Capitalized software	(17.8)	(16.3)	(73.3)	(88.0)
Free cash flow	\$47.8	(\$28.3)	\$169.7	(\$92.7)

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with U.S. generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents non-GAAP gross profit, income from operations, Adjusted EBITDA, Adjusted EBITDA margin, effective income tax rate, net income, diluted earnings per share and free cash flow, which are considered non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. The definitions of non-GAAP financial measures are presented below:

- Non-GAAP gross profit consists of GAAP gross profit, as reported, and excludes acquisition-related amortization; stock-based compensation expense and restructuring and other costs. Non-GAAP gross margin consists of non-GAAP gross profit as a percentage of revenue in the applicable period. Reconciliations to GAAP gross profit are found in Table 4 within this press release.
- Non-GAAP income from operations consists of GAAP income (loss) from operations, as reported, and excludes acquisition-related amortization; stock-based compensation expense; and restructuring and other costs. Reconciliations to GAAP income (loss) from operations are found in Table 4 within this press release.
- Adjusted EBITDA is a non-GAAP measure and consists of GAAP income/(loss) from operations, as reported, and adjusts for: depreciation and amortization; asset impairment charges; stock-based compensation expense; and restructuring and other costs. Reconciliations to GAAP income/(loss) from operations are found in Table 5 within this press release.
- Adjusted EBITDA margin is a non-GAAP measure that is calculated by dividing Adjusted EBITDA by revenue. See the reconciliations in Table 5 within this press release with respect to Adjusted EBITDA.
- Non-GAAP effective income tax rate is based on non-GAAP pre-tax earnings and consists of the statutory federal income tax rate, Allscripts effective state income tax rate and adjustments for permanent differences.
- Non-GAAP net income attributable to Allscripts Healthcare Solutions, Inc. consists of GAAP net income/(loss) from continuing operations, as reported, and adds back acquisition-related amortization; stock-based compensation expense; restructuring and other costs; and non-cash charges to interest expense and other. Non-GAAP net income also includes a GAAP to non-GAAP tax rate alignment adjustment. Reconciliations to GAAP net income/(loss) attributable to Allscripts Healthcare Solutions, Inc. are found in Table 4 within this press release.
- Non-GAAP diluted weighted shares outstanding consists of diluted weighted shares outstanding, as reported, less the effect of the capped call hedges related to the 0.875% Convertible Notes.
- Non-GAAP diluted earnings per share consist of non-GAAP net income, as defined above, divided by non-GAAP diluted weighted shares outstanding, as defined above, during the applicable period.
- Free cash flow consists of GAAP cash flows from continuing operations in the applicable period, net of capital expenditures and capitalized software costs. Reconciliations to GAAP cash flows from continuing operations are found in Table 6 within this press release.

Acquisition-Related Amortization. Acquisition-related amortization expense is a non-cash expense arising primarily from the acquisition of intangible assets in connection with acquisitions or investments. Allscripts excludes acquisition-related amortization expense from non-GAAP gross profit, non-GAAP operating income, and non-GAAP net income because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods because of new acquisitions and full amortization of previously acquired intangible assets. Investors should note that the use of these intangible assets contributed to revenue in the periods presented and will contribute to future revenue generation, and the related amortization expense will recur in future periods.

Stock-Based Compensation Expense. Stock-based compensation expense is a non-cash expense arising from the grant of stock-based awards. Allscripts excludes stock-based compensation expense from non-GAAP gross profit, non-GAAP operating income, non-GAAP net income and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods as a result of the timing and valuation of grants of new stock-based awards, including grants in connection with acquisitions. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods, and such expense will recur in future periods.

Restructuring and Other Costs. Restructuring and other costs relate to certain legal proceedings and investigations, consulting, severance, incentive compensation and other charges incurred in connection with activities that are considered not reflective of our core business. Other costs also include non-cash impairment charges based on management's assessment of the likelihood of near-term recovery of the investments' value.

Allscripts excludes restructuring and other costs, in whole or in part, from non-GAAP gross profit, non-GAAP operating income, non-GAAP net income and Adjusted EBITDA because it believes (i) the amount of such expenses in any specific period may not directly correlate to the underlying performance of Allscripts business operations and (ii) such expenses can vary significantly between periods.

Asset Impairment Charges. Asset impairment charges reflect non-cash charges related to the write-offs of deferred costs related to our private cloud hosting operations.

Non-Cash Charges to Interest Expense and Other. Non-cash charges to interest expense include the amortization of the fair value of the conversion option embedded in the 0.875% Convertible Notes issued by Allscripts during the fourth quarter of 2019. Other includes certain other income and expense and impairments on long-term investments.

Tax Rate Alignment. Tax rate alignment aligns the applicable period's effective tax rate to the expected annual non-GAAP effective tax rate.

Management also believes that non-GAAP gross profit, income from operations, effective income tax rate, net income, diluted earnings per share, Adjusted EBITDA, Adjusted EBITDA margin and free cash flow provide useful supplemental information to management and investors regarding the underlying performance of Allscripts business operations. Acquisition accounting adjustments, restructuring, and other costs recorded in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments provided and discussed herein.

Management also uses this information internally for forecasting and budgeting, as it believes that these measures are indicative of core operating results. In addition, management may use non-GAAP gross profit, operating income, net income, diluted earnings per share, Adjusted EBITDA and/or Adjusted EBITDA margin to measure achievement under Allscripts stock and cash incentive compensation plans. Note, however, that non-GAAP gross profit, operating income, net income, diluted earnings per share, Adjusted EBITDA and Adjusted EBITDA margin are performance measures only, and they do not provide any measure of cash flow or liquidity. Allscripts considers free cash flow to be a liquidity measure that provides useful information to management and investors about the amount of cash generated by the business after capital expenditures and capitalized software costs. Free cash flow provides management and investors a valuable measure to determine the quantity of capital generated that can be deployed to create additional shareholder value by a variety of means. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the definitions and reconciliations of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.

Contacts

Investors:

Jenny Gelinias

312-506-1237

Jenny.Gelinias@allscripts.com

Media:

Concetta Rasiarmos

312-447-2466

concetta.rasiarmos@allscripts.com